Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Clinical Therapeutics|February 6, 2022
Establishing PK Equivalence Between Adalimumab and ABP 501 in the Presence of Antidrug Antibodies Using Population PK ModelingSameer Doshi, Hui Wang, Vincent ChowJournal of Clinical Pharmacology|October 1, 2010
Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysisSameer Doshi, Andrew Chow, Juan José Pérez RuixoBritish Journal of Clinical Pharmacology|January 16, 2019
Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapyMita Kuchimanchi, Min Zhu, John D Clements, et al.Journal of Pharmacokinetics and Pharmacodynamics|July 23, 2022
Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation modelMario Nagase, Sameer Doshi, Sandeep Dutta, et al.CPT: Pharmacometrics & Systems Pharmacology|October 20, 2023
A multistate platform model for time-to-event endpoints in oncology clinical trialsChih-Wei Lin, Mario Nagase, Sameer Doshi, et al.Journal of Clinical Pharmacology|February 25, 2015
Quantitative pharmacology of denosumab in patients with bone metastases from solid tumorsJuan Jose Perez Ruixo, Sameer Doshi, Winnie Sohn, et al.CPT: Pharmacometrics & Systems Pharmacology|April 23, 2026
Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEMChih-Wei Lin, Po-Wei Chen, Sameer Doshi, et al.Clinical Pharmacokinetics|November 4, 2019
Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological MalignanciesJohn David Clements, Min Zhu, Mita Kuchimanchi, et al.Journal of Clinical Pharmacology|April 25, 2015
Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic modelLiviawati Wu, Diane R Mould, Juan Jose Perez Ruixo, et al.Clinical Pharmacokinetics|April 9, 2016
Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic PerspectiveBing-Bing Yang, Sameer Doshi, Karen Arkam, et al.Pageof 4